How Indianapolis Quietly Built One of the World's Deepest Biologics Ecosystems

When you think of American biotech hubs, you probably think of Boston/Cambridge, the San Francisco Bay Area, or Research Triangle Park. Indianapolis rarely makes the list. It should.

For more than a century, the city has quietly built one of the deepest life sciences ecosystems in the world — producing discoveries that transformed diabetes care, psychiatry, and obesity medicine, and generating extraordinary economic value in the process. The story of how that happened is a case study in how scientific talent, patient capital, and institutional persistence can compound across generations.

The Peptide Pioneer

Richard DiMarchi earned his PhD from Indiana University in 1979, then completed postdoctoral training under Bruce Merrifield at Rockefeller University — whose pioneering work in solid-phase peptide synthesis earned the 1984 Nobel Prize in Chemistry. DiMarchi brought that expertise back to Indianapolis, joining Eli Lilly and Company, where he would spend more than two decades advancing peptide science and eventually rise to Vice President of Research and Development.

His most consequential early contribution was Humalog, a rapid-acting insulin analog that transformed diabetes management. By redesigning the insulin molecule to absorb more quickly after injection, Humalog gave patients flexibility around mealtimes that older formulations couldn't match. The National Inventors Hall of Fame inducted DiMarchi specifically for this invention.

But the bigger story was still to come.

The Discovery That Was Ahead of Its Time

During his years at Lilly, DiMarchi collaborated with the late Suad Efendic of Sweden's Karolinska Institute to study a hormone called GLP-1 (glucagon-like peptide-1). Their research revealed something unexpected: GLP-1 therapies helped overweight diabetic patients lose weight while improving blood sugar control — an observation now recognized as one of the foundational scientific advances behind the entire GLP-1 drug class.

The problem was timing. This was the 1990s and early 2000s. Obesity was not yet widely classified as a chronic disease. Weekly injectable therapies were an unfamiliar treatment model. The pharmaceutical industry hadn't caught up to the science. As Science magazine reported in its coverage of the AAAS award, DiMarchi synthesized GLP-1 compounds for Efendic's clinical trials, which demonstrated the weight-loss signal — but the broader market wasn't ready.

Like many transformative discoveries, the science arrived years before the market could absorb it.

From Lilly to Academia — and the Novo Nordisk Connection

After an early retirement from Eli Lilly, DiMarchi continued advancing peptide research through collaborations with Novo Nordisk's Indianapolis-based research organization before joining Indiana University as the Linda and Jack Gill Chair in Biomolecular Sciences and a Distinguished Professor of Chemistry.

At Novo Nordisk, scientist Lotte Bjerre Knudsen carried the GLP-1 thread forward. Over decades of work, Knudsen engineered semaglutide — the molecule marketed as Ozempic (for diabetes) and Wegovy (for obesity). The scientific lineage runs directly from DiMarchi and Efendic's early weight-loss observation through Knudsen's persistent advocacy at Novo Nordisk, where she fought to prove GLP-1 drugs could treat obesity even when internal skeptics doubted it.

In 2024, the American Association for the Advancement of Science (AAAS) jointly honored DiMarchi and Knudsen with the Golden Brain Award for establishing the scientific foundation that made today's GLP-1 therapies possible. That same year, the Lasker Foundation awarded its Clinical Medical Research Award to three additional GLP-1 pioneers — Joel Habener, Svetlana Mojsov, and Knudsen — underscoring how many scientists contributed to what is now the biggest pharmaceutical class on the planet.

A City Built Around Discovery

DiMarchi's story isn't an outlier. Indianapolis has produced category-defining pharmaceutical innovations across multiple generations:

• 1923: Eli Lilly became the first large-scale commercial producer of insulin, just two years after Banting and Best's discovery.
• 1982: Lilly introduced Humulin, the world's first recombinant DNA-derived human insulin — and the first recombinant pharmaceutical ever approved by the FDA. It replaced 60 years of animal-derived insulin with a reliable biotechnology-based therapy.
• 1988: Lilly launched Prozac, which transformed the treatment of depression and became one of the most prescribed drugs in history.
• 2022–present: Lilly's tirzepatide (Mounjaro/Zepbound) — a dual GLP-1/GIP agonist — has become one of the most successful medicines in pharmaceutical history, competing directly with Novo Nordisk's semaglutide franchise.

These breakthroughs reflect decades of sustained investment in scientific talent, peptide chemistry, academic research, and advanced manufacturing. Indiana University, Eli Lilly, and numerous public and private organizations created an ecosystem where knowledge stayed in the region — one generation of researchers training the next, continually expanding the state's life sciences capabilities.

Organizations like BioCrossroads have reinforced this foundation by connecting research institutions, corporations, investors, and entrepreneurs throughout Indiana's life sciences community. Their mission reflects an important reality: scientific leadership is not self-sustaining. It requires patient capital, experienced leadership, and continued investment in future generations.

When Biology Creates Philanthropic Scale

Perhaps the most remarkable illustration of biologics' economic power sits outside the laboratory entirely.

The Lilly Endowment, created in 1937 through gifts of Eli Lilly and Company stock by J.K. Lilly Sr. and his sons, has grown into the largest private philanthropic endowment in the United States — and the third-largest in the world — with assets exceeding $102 billion as of early 2026. It remains the largest shareholder of Eli Lilly and Company, meaning a groundbreaking pharmaceutical company continues to fuel one of the world's most influential charitable foundations.

Remarkably, the two largest pharmaceutical endowments in the world both trace their wealth to diabetes medicines. Denmark's Novo Nordisk Foundation — with approximately $109 billion in assets as of year-end 2025 — owes much of its growth to the global success of Ozempic and Wegovy. Together, these two endowments control over $200 billion in philanthropic capital, all ultimately derived from the science of insulin and GLP-1.

As Lilly's scientific and commercial success created long-term shareholder value, the Endowment's resources expanded alongside it — enabling billions in charitable grants supporting education, community development, religion, and public initiatives. A breakthrough developed in a research laboratory improved patient outcomes, created jobs, strengthened universities, rewarded long-term investors, and generated philanthropic resources that continue serving communities decades later.

The Next Chapter: Biology Meets Compute

The next era of biologics innovation won't be driven by laboratory research alone. Protein structure prediction (exemplified by DeepMind's AlphaFold), peptide engineering, molecular simulation, and AI-assisted drug discovery now rely on enormous amounts of computing power, advanced data infrastructure, and reliable energy systems.

As biology and artificial intelligence converge, access to high-performance computing will become an increasingly important component of medical innovation. Just as Indianapolis built lasting advantages through scientific talent and long-term investment over the past century, the next generation of breakthroughs will be shaped by the infrastructure that enables discovery itself — compute, data, and power.

The Indianapolis story offers a broader lesson for biotech investors and operators: great scientific ecosystems are built patiently, over decades, through the compounding interaction of research institutions, industry, entrepreneurs, patient capital, and philanthropy. The cities that invest in that full stack — not just in individual discoveries — are the ones that shape the future of medicine.

Source material and research perspective contributed by Eliakim Capital. Independent reporting and verification by The Daily Biologics.

---

Rich Washburn works at the intersection of AI, infrastructure, and capital. He holds dual CIO roles at Eliakim Capital and Data Power Supply, where he architects and funds AI systems and the physical infrastructure required to deploy them. He has spent three decades building and advising on complex technical systems — from digital forensics and cybersecurity to high-performance compute and experimental hardware. Read more at richwashburn.com